Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $65.00 price target on the stock.
Avidity Biosciences, Inc. (NASDAQ: RNA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
Avidity Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]